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Patents and the quality, safety and efficacy of medicines
A patent represents a right or title conferred by 
a government authority granting an inventor a 
limited period of exclusive use of a patented 
invention, in return for full public disclosure of the 
invention.[1] The premise is to stimulate innovation 
by ensuring that the inventor has a limited monopoly as a 
reward for advancing the industry.[2] Innovative research in the 
pharmaceutical industry is extremely costly and time consuming. 
It is generally accepted that the resulting innovations are better 
rewarded in countries with advanced patent systems than in 
countries where patent protection is still lacking. Innovation 
leads to innovation when other inventors have the opportunity to 
advance the technology disclosed in patents further, and patent 
their own innovations in turn. However, sometimes the working 
of these patents may require cross­licensing between the patentees 
(Patents Act,[3] section 55).
Patent requirements and applications
To be patentable an invention must be new, involve an inventive step, 
and have the capability of being used or applied in trade, industry 
or agriculture (Patents Act,[3] section 25). The specific form and 
requirements of a patent application vary for each country. Generally, 
all patent applications can be divided into two major parts. Firstly, 
a patent will contain a detailed disclosure in order to enable a 
person of ordinary skill in the pertinent area to make and use the 
invention without extensive experimentation.[4] Secondly, and most 
importantly, a patent contains a set of worded claims that defines the 
scope of the monopoly and thus the protection applied for. Whether 
or not a patent is granted almost always depends on whether the 
subject matter of the claims is novel and inventive in comparison with 
what came before (Patents Act,[3] section 25).
In the pharmaceutical field, groups of patents may be granted 
starting with the development of a novel active pharmaceutical 
ingredient. For example, an active ingredient and its synthesis may 
be patented, followed by patents protecting the formulation of the 
final product containing the active ingredient and the manufacturing 
process of the final product. Even after the initial patent has expired, 
the formulation and manufacturing process of the final product may 
therefore still be protected, impacting on generic manufacturers.
Abuse of the patent system
South Africa (SA) is not an examining country, which means that 
the content of patent applications is not examined to determine 
whether they meet the requirements for patentability. However, lack 
of patentability is grounds on which an application for revocation of 
a patent may be lodged (Patents Act,[3] section 61). A patent may also 
be revoked on grounds that the invention as illustrated or exemplified 
in the patent document cannot be performed or does not lead to the 
results and advantages set out (Patents Act,[3] section 61). A patent 
has to fully disclose the invention in return for the monopoly granted.
Furthermore, the Patents Act makes provision for any interested 
person who is able to show that the rights in a patent are being 
abused to apply to the commissioner for a compulsory licence 
under the patent (Patents Act,[3] section 56). The rights in a patent 
are deemed to be abused for various reasons. An example is that 
the patented invention is not being worked in SA on a commercial 
scale or to an adequate extent, after the expiry of a period of 4 years 
subsequent to the date of the application for the patent, or 3 years 
subsequent to the date on which that patent was sealed, whichever 
period expires last, and if in the opinion of the commissioner 
there is no satisfactory reason for such non­working (Patents 
Act,[3] section 56). The Patents Act therefore contains provisions to 
prevent the abuse of patents.
Patent infringement v. circumvention
In SA, as in most countries around the world, a patent is infringed 
when a product or process that falls within the scope defined by 
the claims is made, used, offered for sale, sold or imported, without 
permission, in the country where the patent has been granted 
(Patents Act,[3] sections 45 and 65). In order to determine whether a 
product falls within the defined scope of a patent, a list of essential 
features are isolated within the wording of the claims in the patent, 
and if all these essential features are present in the product or process 
under consideration, the patent has been infringed.[5,6] The patentee 
has the right to institute proceedings for infringement in these 
circumstances.
The model set out above creates an interesting conundrum in the 
pharmaceutical industry, where competitors are provided with a 
detailed description of all the products that are developed, as well as 
a list of essential features that defines the scope of patent protection. 
Players in this industry sometimes devote time and money to analyse 
the inventions of their competitors in order to determine whether 
they can produce similar products with similar effects, by doing 
without one of the essential features that defines the scope of patent 
protection. If this can be achieved, a company can piggy­back on 
the research of a competitor without investing the same time and 
resources. This is known as competitive patent circumvention, which, 
if successfully conducted, does not lead to patent infringement and 
is not unlawful but may affect the medicine’s quality, safety and/or 
efficacy.
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Circumvention of patents and its 
effect on quality, safety and efficacy  
of medicines
Registration of a medicine in SA provides the assurance that the 
medicine meets the quality and safety requirements and is effective 
for its intended purpose. The quality of a medicine includes attributes 
such as identity, strength and purity, which are incorporated into an 
approved set of standards against which the medicine is tested.[7] If a 
medicine consistently meets these standards, it is a quality medicine.
Furthermore, medicines should be safe and efficacious in order 
for them to be acceptable for patient use. Safety is the ability of the 
medicine not to cause unprecedented harm or serious side­effects, 
when measured against the risk­benefit profile of the medicine. 
Side­effects of a medicine are often due to the inherent properties 
of the active pharmaceutical substance/s it contains.[8] Efficacy, on 
the other hand, is simply an expression used to determine whether 
the medicine is useful for its intended purpose.[9] Efficacy therefore 
means that the medicine meets its therapeutic claim.[10] A combi­
nation of carefully designed, and conducted in vitro, animal and 
clinical studies assist in identifying undesirable and toxic effects of a 
medicine, and also its efficacy.[11]
Quality, safety and efficacy studies are conducted to support the 
registration of a medicine. The medicines regulatory authority (MRA) 
in SA ensures that all the requirements for quality, safety and efficacy 
are met before granting registration. The requirements set by the 
MRA often give rise to the development of innovative formulations 
and manufacturing procedures, which are patented separately from 
the active pharmaceutical ingredient. This creates a challenge for 
generic manufacturers who wish to manufacture a generic medicine 
after the expiry of the patent that protected the active pharmaceutical 
ingredient/s of the medicine. A new and innovative formulation 
or process has to be established for the generic medicine which is 
qualitatively and quantitatively similar to the innovator medicine 
without infringing the patent protecting this formulation or process.
In practice the development of these new formulations may prove 
troublesome. For example, a pharmaceutical patent may stipulate a specific 
excipient, and in an effort to circumvent the patent a generic medicine 
manufacturer will have to use another excipient. If an effective excipient 
cannot be found during product development, the product may present 
with both safety and efficacy issues following poor­quality formulation.
Another example is that a specific impurity limit may be claimed for 
an active ingredient. An effort to circumvent such a patent may result 
in the intentional contamination of the active ingredient to raise the 
quantity of the impurity above the patented limits. This intentional 
contamination compromises quality and violates good manufacturing 
and regulatory process, even if the quantity of the impurity introduced 
is not significant and will not present safety or efficacy concerns. 
Compromising quality may result in safety concerns and efficacy 
problems, especially in cases where patients respond differently to the 
same active substance and in drugs with a narrow therapeutic index.
Conclusion
The impact of patent circumvention potentially has serious impli­
cations with regard to medicine quality, safety and efficacy, even 
if it was intended to improve accessibility and affordability of 
these medicines. Although the MRA does not have any man­
date with regard to patents, it has a mandate to protect the 
public. Efforts to circumvent patents sometimes increase the 
regulatory burden of monitoring product quality, safety and 
efficacy. Furthermore, a lack of efficacy caused by efforts to 
circumvent patents protecting formulations or processes may 
result in subtherapeutic levels of medicines, resulting in obvious 
health risks. For example, ineffective asthma medication may 
result in death, and subtherapeutic levels of antiepileptics or 
antibiotics will result in relapses and drug resistance, respectively. 
The impact of patent circumvention has far­reaching effects on 
public health.
Companies should therefore conduct adequate research in order 
to understand the effect of patent circumvention on the quality, 
safety and efficacy of medicine. Sufficient research is necessary to 
develop alternative formulations and processes, which have to be 
appropriately validated using production scale batches. Further­
more, sufficient stability data (including stress testing) has to be 
generated. These steps are necessary to ensure production of a 
quality product that will not during any stage of its life cycle fail 
in terms of quality, compromise patient safety, or be ineffective.
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